Home > Boards > US OTC > Delisted >

Innovus Pharmaceuticals Inc. (fka INNV)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, gi197845
Search This Board: 
Last Post: 3/13/2020 11:46:27 AM - Followers: 143 - Board type: Free - Posts Today: 0


*32 Products in USA / 12 Internationally*

 www.innovuspharma.com (Website)


* shareholders, please consider purchasing product(s)

 2018 Net Revenue Guidance of ~$23M (Up from $8.8M in 2017)


Innovus Pharma Launches FlutiCare OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.

FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.

“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.

FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.

FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.

About FlutiCare™

FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.

** FlutiCare contains the nasal steroid API that is physician recommended and consumer preferred **

  • #1 form used by patients;
    #1 nasal steroid active prescribed by physicians;
    Familiar to patients, comfort of a known & trusted medicine;
    Engrained in patients’ allergy management; and
    Effective and safe.



Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.  President and Chief Executive Officer:                           

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?

Management Team


* Bassam Damaj, Ph.D.

President and Chief Executive Officer

Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was partof the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.


* Randy Berholtz, M.B.A./J.D.

Executive Vice President, Corporate Development and General Counsel

In addition to his responsibilities as Executive Vice President and Corporate Development and General Counsel, Randy Berholtz is also the Secretary of the company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President and General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and U.S. life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company, and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms, including Heller Ehrman LLP, Cooley LLP, Kirkpatrick & Lockhart LLP (now K&L Gates LLP) and Cravath, Swaine & Moore LLP. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University (he was a Rhodes Scholar), and a Juris Doctor degree from Yale Law School - where he was a Senior Editor of the Yale Law Journal - and an MBA from the University of San Diego School of Business.

* Ryan Selhorn, CPA

Vice President, Chief Financial Officer

Ryan has served as our Vice President and Chief Financial Officer since April 27, 2018. From July 2013 to April 2018, he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.

* Christopher Stella

Vice President of Operations

Christopher Stella has served as our Vice President of Operations since June 2018. From February 2014 to June 2018 he was President and CEO of Stella Marketing Group, a specialty marketing firm supporting the natural products industry including major public and private health and beauty companies advertising through various direct-to-consumer channels. One of which, Innovus Pharmaceuticals, where he worked directly with management and helped the company exceed revenue targets in both 2017 and 2018. From September 2013 to February 2014, he worked at Nutraclick, a technology-driven health and wellness products company, where he developed the marketing campaigns for their four leading brands found in both major retail outlets such as GNC, Walmart and CVS and popular ecommerce platforms. Mr. Stella received his Bachelor of Economics from the University of Massachusetts (Suma Cum Laude) at Amherst with minors in both Chinese and Finance from the School.

info@innovuspharma.com  (email)

Share Structure:

Low Floater

Profitability expected exiting 2019 !
- 2018 Projected Revenue of $23M, smashing $8.8M for all of 2017 
- 78%+ Gross Margin

Products for Purchase:




Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call






Innovus Pharma (INNV): Targeting Multiple Billion Markets With Commercial Products


Prior Accomplishments:





Existing Product Lines @ Innovus Pharma:




PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.

- WHAT IS DiabaSens™?______________________________________________________________________________________________________________

DiabaSens™ is a patent-pending advanced, all-natural cream specifically formulated to increase nerve sensation and blood flow in men and women of all ages. Its proprietary blend of key ingredients has been clinically tested to increase sensation of the skin and improve blood flow where applied. DiabaSens™ was developed by top medical researchers and produced in a top-quality, cGMP-certified and FDA-registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in DiabaSens™ have been published in leading medical journals.

Are you looking to boost your brain health?r

UriVArx® Bladder Control and Function 

http://www.myandroferti.com/  - (In a dozen CVS "pilot" stores)

https://www.myvesele.com/ - (Better SEX, WOW-Z'ers)


** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company   

Image result for images of love                    Products ship world-wide - support YOUR company                                                                               



#20469  Sticky Note I calculated $2.30/sh in an all stock deal Drugdoctor 09/12/19 10:47:01 AM
#20612   3/12/20 Zack recommended buy. 3/13 last 1.35. mynah 03/13/20 11:46:27 AM
#20611   Of all the stocks I am watching, aytu mynah 03/12/20 05:28:38 PM
#20610   Talk about being saved by the bell! Roland Rick Perry 03/10/20 01:58:44 PM
#20609   AYTU LAST $1.90 over 100 million shares traded mynah 03/10/20 12:57:36 PM
#20608   3/10/20 11:43 EST AYTU last $1.17 mynah 03/10/20 11:43:46 AM
#20607   3/10/2020 Cisco Kid Are you covering your short position? mynah 03/10/20 11:35:03 AM
#20606   INNV shareholders get about .90 in AYTU shares... Drugdoctor 02/14/20 09:00:54 PM
#20605   Thank goodness, now this scam is done for Drugdoctor 02/14/20 08:57:04 PM
#20604   INNV: Merged with Aytu BioScience, Inc. (AYTU); Shareholders Renee 02/14/20 06:09:35 PM
#20603   Well, Innovus was a scam from the beginning, gi197845 02/12/20 12:07:56 PM
#20602   But they have plenty-of-this to sell, lol>>> Drugdoctor 02/11/20 11:47:28 PM
#20601   Search for fluticare anywhere. It's out of stock, gi197845 02/11/20 10:23:20 PM
#20600   Fluticare is gone? SMH kkpennies 02/11/20 10:16:16 PM
#20599   Well, you do realize, that with these snake-oil, gi197845 02/11/20 10:15:00 PM
#20598   Pretty sure I need this to go to kkpennies 02/11/20 12:19:39 PM
#20597   Maybe it's time for the tax losses selling? Drugdoctor 02/05/20 10:55:07 PM
#20596   Does anyone here think thee INNV share price gi197845 02/03/20 11:08:47 AM
#20595   LOL, I was joking, just trying to get gi197845 01/30/20 10:11:05 PM
#20594   Nowhere in the I-hub Terms of Service does Drugdoctor 01/30/20 07:35:49 PM
#20593   Board moderator here: gi197845 01/29/20 10:21:35 PM
#20592   Innovus voting on 02/13/2020. gi197845 01/29/20 02:30:08 PM
#20591   Whatever they pay for scam $INNV it will Drugdoctor 01/22/20 07:50:27 PM
#20590   AYTU were supposedly paying up to $8.0MM less ROCKHard 01/22/20 06:28:26 PM
#20589   Correct! Lying scumbag POS. Should be dragged into the jbdiver 01/12/20 07:07:31 PM
#20588   Just don't be patient with lying POS CEO's Drugdoctor 01/11/20 02:55:12 PM
#20587   Haha... biggest turd stock to have ever crossed jbdiver 01/11/20 10:08:31 AM
#20586   Guess you don't believe they will be bigly Honeycomb777 01/08/20 01:10:03 PM
#20585   JB, sorry to hear that, I concluded the snupoled 01/04/20 02:32:24 PM
#20584   INNVD as in INNV is a type of gi197845 01/02/20 10:55:08 AM
#20583   Put market order to sell my entire position jbdiver 12/26/19 09:06:15 AM
#20582   The reason AYTU did that is because of ShawnP123 12/24/19 10:42:11 AM
#20581   Merger NEWS out... lmao... Aytu will retire all Drugdoctor 12/24/19 08:40:23 AM
#20580   Dr.D used our investment money and the r/s gi197845 12/23/19 02:10:57 PM
#20579   No one should have expected anything different from ShawnP123 12/23/19 11:47:01 AM
#20578   Wonder how bad the losses are piling up Drugdoctor 12/23/19 11:29:30 AM
#20577   Was there another reverse split? Is that why gi197845 12/19/19 06:54:53 PM
#20576   The Cisco Kid is happy. His short mynah 12/16/19 11:23:39 PM
#20575   I've sold a lot of fluticisone spray, but Drugdoctor 12/15/19 04:02:35 PM
#20574   All the more reason why INNV will merge gi197845 12/15/19 02:55:15 PM
#20573   $INNV merger partner $AYTU being investigated... lol Drugdoctor 12/15/19 03:10:57 AM
#20572   I still stick by my comment that it gi197845 12/14/19 06:33:33 PM
#20571   Actually, the market is closed, so the active Drugdoctor 12/14/19 07:40:41 AM
#20570   It's really dumb that the bid is at gi197845 12/14/19 01:02:29 AM
#20569   $AYTU is down 50% since the merger-agreement-with-$INNV... They Drugdoctor 12/10/19 01:09:29 PM
#20568   Hi, in my opinion, having been invested in gi197845 12/07/19 12:25:11 PM
#20567   Very plausible. jtaylor68 12/06/19 10:17:08 PM
#20566   RH- This will end up below 0.35 after ShawnP123 12/06/19 03:31:42 PM
#20564   Would 35 cent bid get interest as ROCKHard 12/05/19 10:38:52 PM
#20563   Over the past couple of years, I used gi197845 12/05/19 08:54:02 PM
#20562   Gonna get worse ShawnP123 12/05/19 03:30:56 PM